Adaptive Nanocarriers for Personalized Cancer Treatment
Legal Citation
Summary of the Inventive Concept
A next-generation nanocarrier system that dynamically adjusts to real-time tumor microenvironment data, enabling precision cancer therapy through adaptive porosity, self-healing surfaces, and programmable release profiles.
Background and Problem Solved
The original patent disclosed a nanomedicinal composition for treating breast cancer, but its fixed porosity and release profile limitations hindered its effectiveness in diverse cancer scenarios. The new inventive concept addresses these limitations by envisioning a system that adapts to the complex and dynamic tumor microenvironment, providing a more personalized and effective cancer treatment.
Detailed Description of the Inventive Concept
The inventive concept comprises a nanocarrier with adaptive porosity, self-healing surface, or programmable release profile, which can be dynamically adjusted based on real-time tumor microenvironment data. The nanocarrier is designed to release a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant in response to the adaptive porosity or self-healing surface. Additionally, the nanocarrier can be programmed to emit therapeutic radiation or communicate with other nanocarriers to optimize treatment efficacy.
Novelty and Inventive Step
The new claims introduce a paradigm shift in nanocarrier design, enabling real-time adaptation to the tumor microenvironment. The adaptive porosity, self-healing surface, and programmable release profile features are novel and non-obvious compared to the original patent, providing a significant improvement in precision cancer therapy.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include nanocarriers with different adaptive mechanisms, such as pH-responsive or temperature-sensitive surfaces. Variations could also involve different pharmaceutical agent mixtures or external triggers for therapeutic radiation emission.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the cancer treatment market, particularly in personalized medicine and precision oncology. Target industries include pharmaceutical companies, biotechnology firms, and medical device manufacturers.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/6923 |
| A | A61 | A61K31/138 |
| A | A61 | A61K31/282 |
| A | A61 | A61K33/243 |
| A | A61 | A61K47/10 |
| A | A61 | A61K2121/00 |
| A | A61 | A61K2800/47 |
| B | B82 | B82Y5/00 |
| B | B82 | B82Y25/00 |
| B | B82 | B82Y30/00 |
| B | B82 | B82Y40/00 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Nanomedicine, specifically targeted cancer therapeutics involving nanocarrier drug delivery systems with advanced materials engineering and pharmaceutical formulation
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in materials science, chemical engineering, or pharmaceutical sciences, possessing expertise in nanoparticle design, drug delivery mechanisms, and cancer treatment strategies
Obviousness Rationale
A person having ordinary skill would recognize that the PTD's adaptive nanocarrier variations represent predictable extensions of the source patent's core nanocarrier technology, leveraging known techniques in responsive materials, programmable drug delivery, and precision medicine approaches. The fundamental structural elements of the nanosilicate matrix and magnetic nanoparticle composition remain consistent, with the PTD introducing incremental technological improvements that would be apparent to a skilled practitioner seeking to optimize cancer treatment strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,639 |
|---|---|
| Title | Method for treating breast cancer |
| Assignee(s) | Imam Abdulrahman Bin Faisal University |